Ardelyx (ARDX) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verastem (VSTM) has outperformed Ardelyx (ARDX) over the past year, losing 9.3% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -75.5% for VSTM. Ardelyx is the larger company by market cap ($844.3 million vs $734.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | VSTM |
|---|---|---|
| Share price | $3.27 | $8.11 |
| Market cap | $844.27M | $734.47M |
| 1-day change | +0.31% | -1.88% |
| YTD return | -43.91% | +5.05% |
| 1-year return | -35.38% | -9.28% |
| 5-year return | +202.78% | -75.51% |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $10.82 |
| 52-week low | $3.18 | $3.43 |
| Distance from 52-week high | -61.07% | -25.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.50% | +84.96% |
| Average volume | 4.17M | 2.25M |
| Shares outstanding | 258.19M | 90.56M |
| Employees | 489 | 102 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VSTM has outperformed ARDX by 26.1 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Healthcare · Biotechnology · 489 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
ARDX vs VSTM FAQ
Which is bigger, Ardelyx or Verastem?
Ardelyx (ARDX) is larger, with a market capitalization of $844.27M compared with $734.47M for Verastem (VSTM).
Which stock has performed better over the past year, ARDX or VSTM?
VSTM returned -9.28% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Verastem in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.